Repurposing Metformin as a Leukemia-preventive Drug in CCUS and LR-MDS

Cytopenia Clinical Trial

Official title:

STOP-LEUKEMIA: Repurposing Metformin as a Leukemia-preventive Drug in CCUS and LR-MDS

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04741945
• Other study ID #: STOP-LEUKEMIA
• Status: Recruiting
• Phase: Phase 2
• Start date: December 13, 2021
• Est. completion date: June 2026

Study information

• Verified date: July 2023
• Source: Rigshospitalet, Denmark
• Contact: Kirsten Grønbæk, Professor, MD
• Phone: +45 35456060
• Email: Kirsten.Groenbaek[@]regionh.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single-arm pilot study of the feasibility and safety of metformin in patients with clonal cytopenia of undetermined significance (CCUS) or lower-risk myelodysplastic neoplasms (LR-MDS).

Description:

The research plan is divided into three work packages (WP):

WP0: Bone Marrow Adipose Tissue, Gut Microbiota, and Intestinal Permeability in CCUS and LR-MDS Patients.

The aim of WP0 is to investigate biological features which the investigators hypothesize to be of pathogenetic relevance for MDS progression and may be possible targets of metformin treatment. For this purpose, 20 elderly (≥60 years) healthy controls will be included for comparison to patients with CCUS or LR-MDS from WP1.

The primary objectives are to investigate 1) the abundance and properties of bone marrow adipose tissue (BMAT) and bone marrow (BM) adipocytes, and 2) the gut microbiota and intestinal permeability of patients with CCUS or LR-MDS compared to age-, sex- and body mass index (BMI)-matched healthy controls. Secondary objectives are to characterize DNA methylation and hydroxymethylation (5-mC and 5-hmC) patterns, and hormone and cytokine levels in BM plasma from healthy controls and patients with CCUS or LR-MDS.

WP1: Safety, feasibility, and mechanisms of action of metformin in patients with CCUS or LR-MDS.

In this WP up to 40 patients with CCUS or LR-MDS will receive metformin 2000 mg daily or their maximum tolerated dose (MTD) for 12 months. The aim of WP1 is to investigate safety of metformin and feasibility of the protocol in patients with CCUS or LR-MDS. Potential mechanisms of anti-leukemic action of metformin will also be explored in order to identify a suitable outcome measure and estimate standard deviation of the outcome measure. All in order to inform the design of a future phase 3 RCT of the efficacy of metformin in CCUS and LR-MDS patients. Endpoints of WP1 are specified in the corresponding section.

WP2: Safety and efficacy of metformin compared to placebo. The primary objective of WP2 is to compare safety and preliminary efficacy of metformin in patients with CCUS or LR-MDS to a cohort of patients with CCUS or LR-MDS receiving placebo in context of our EVI-2 randomized, controlled pilot study (NCT03999723).

Data and samples from approximately 50 historical controls will be included from the EVI-2 study in which participants were randomized to receive placebo or oral vitamin C supplement for 12 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: June 2026
• Est. primary completion date: July 2025
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Patients are eligible to be included in WP1 if they meet all of the following criteria:

Inclusion criteria:

• A diagnosis of:

• LR-MDS according to the revised international prognostic scoring system (IPSS-R), i.e., very low- or low-risk disease (IPSS-R score =3) in addition to a bone marrow blast percentage <5 OR

• CCUS defined as the presence of somatic mutation(s) or cytogenetic abnormality not diagnostic of MDS or any other malignancy in the context of persistent cytopenia (>6 months) with other common causes of cytopenia ruled out in the setting of bone marrow morphology that is not diagnostic of MDS or any other malignancy, and hematolytic conditions have been ruled out. Peripheral blood cytopenia is defined as hemoglobin (hgb) <11.3 g/dL (7 mmol/L) in women and hgb <12.9 g/dL (8 mmol/L) in men, platelet count <150 x 109/L, or neutrophil count <1.8 x 109/L

• Menopause, if being a female, defined as females >45 years of age who have experienced amenorrhea for minimum 12 months, without any other obvious pathological or physiological cause

• =18 years of age

• Written informed consent

• Willingness to comply with mandatory aspects of the protocol

• Ability to swallow pills

Exclusion criteria:

• Any prior treatment with metformin

• A diagnosis of diabetes mellitus

• Therapeutic radiation, immunosuppressive therapy (with the exception of corticosteroids), or chemotherapy within the past year

• Treatment with granulocyte colony-stimulating factor within the past 30 days

• Prior therapy with hypomethylating agents (i.e., azacitidine, decitabine)

• eGFR <45 mL/min

• Performance status according to the Eastern Cooperative Oncology Group >2

• Other active malignancy within the past five years

• Uncontrolled comorbidity including impaired hepatic function (total serum bilirubin >1.5 × upper limit of the normal range (ULN), serum alanine transaminase >3 × ULN), chronic hepatitis with decompensated cirrhosis, disabling psychiatric disease, severe neurologic disease, uncontrolled metabolic disease, or severe cardiac disease (NYHA class 3-4)

An eGFR calculation performed up to one month prior to inclusion may be used to assess renal function. If such an assessment is not available, it is performed at screening.

Healthy volunteers are eligible to be included in WP0 if they meet all of the following criteria:

Inclusion criteria:

• Healthy individuals matched on age, sex, and BMI, if possible, to individual patient participants in WP1

• Written informed consent

• Willingness to comply with mandatory aspects of the protocol

Exclusion criteria:

• Use of metformin within the past 3 years

• A diagnosis of diabetes mellitus, rheumatological disorders, autoimmune diseases or other inflammatory disorders, celiac disease, inflammatory bowel disease, or other gastrointestinal disorders or symptoms

• Treatment with immunosuppressive drugs (with the exception of corticosteroids) or chemotherapy within the past year or antibiotics within the past 6 months

• Any contraindications to MRS

Related Conditions & MeSH terms

• Cytopenia
• Leukemia
• Myelodysplastic Syndromes
• Preleukemia

Intervention

Drug:
• Metformin
2000 mg/day metformin for 12 months (1000 mg b.i.d.) with a slow up-titration six weeks prior to full dose treatment.

Locations

Country	Name	City	State
Denmark	Rigshospitalet	Copenhagen	Copenhagen N

Sponsors (8)

Lead Sponsor	Collaborator
Kirsten Grønbæk	Herlev Hospital, Region Hovedstadens Apotek, Steno Diabetes Center Copenhagen, Technical University of Denmark, University of Copenhagen, Van Andel Research Institute, Zealand University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety as assessed by the number of serious adverse events including any suspected unexpected serious adverse reactions	To assess safety of metformin treatment in this off-label indication by the type, grade, and number of adverse events and serious adverse events including any suspected unexpected serious adverse reactions in the patients.	From inclusion to 12 months of study treatment
Primary	Safety as assessed by median maximum tolerated dose in mg/day	To assess safety of metformin treatment in this off-label indication by median maximum tolerated dose and a description of any changes in individual medication doses.	From inclusion to 12 months of study treatment
Primary	Feasibility as assessed by rates of recruitment/refusal rates	To assess feasibility of the study protocol in terms of recruitment and refusal rates.	From inclusion to 12 months of study treatment
Primary	Feasibility as assessed by 12 months follow-up, i.e., study completion, rate	To assess feasibility of the study protocol in terms of rate of study completion.; To assess safety of metformin treatment in this off-label indication by the type, grade, and number of adverse events and serious adverse events including any suspected unexpected serious adverse reactions in the patients; drop-out rates; and a description of any changes in individual medication doses including median maximum tolerated dose.	From inclusion to 12 months of study treatment
Primary	Feasibility as assessed by rate of compliance to protocol procedures	To assess feasibility of the study protocol in terms of rate of adherence to protocol procedures (study medication and study procedures).	From inclusion to 12 months of study treatment
Secondary	Interim efficacy: Mutational burden as assessed by change in variant allele frequency	Change in variant allele frequency (?VAF) by next generation sequencing (NGS)	From inclusion to 12 months of study treatment
Secondary	Interim efficacy: Patient-reported outcome measures based on the EORTC QLQ-C30	Change in patient-reported outcome measures (PROM), based on the validated European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).	From inclusion to 4 months of study treatment
Secondary	Interim efficacy: Patient-reported outcome measures based on the EORTC QLQ-C30	Change in patient-reported outcome measures (PROM), based on the validated European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).	From inclusion to 12 months of study treatment
Secondary	Interim efficacy: Patient-reported outcome measures based on the SF-36	Change in patient-reported outcome measures (PROM), based on the validated Short Form 36 Health Survey Questionnaire (SF-36).	From inclusion to 4 months of study treatment
Secondary	Interim efficacy: Patient-reported outcome measures based on the SF-36	Change in patient-reported outcome measures (PROM), based on the validated Short Form 36 Health Survey Questionnaire (SF-36).	From inclusion to 12 months of study treatment
Secondary	Interim efficacy: Patient-reported outcome measures based on the EQ-5D	Change in patient-reported outcome measures (PROM), based on the validated European Quality of Life Five Dimension questionnaire (EQ-5D).	From inclusion to 4 months of study treatment
Secondary	Interim efficacy: Patient-reported outcome measures based on the EQ-5D	Change in patient-reported outcome measures (PROM), based on the validated European Quality of Life Five Dimension questionnaire (EQ-5D).	From inclusion to 12 months of study treatment
Secondary	Interim efficacy: Bone marrow adipose tissue as assessed by MR spectroscopy ratio of adipose tissue and water phase	Change in bone marrow adipose tissue (BMAT) content in bone marrow (BM) measured by MR spectroscopy	From inclusion to 4 months of study treatment
Secondary	Interim efficacy: Bone marrow adipose tissue as assessed by MR spectroscopy ratio of adipose tissue and water phase	Change in bone marrow adipose tissue (BMAT) content in bone marrow (BM) measured by MR spectroscopy	From inclusion to 12 months of study treatment
Secondary	Interim efficacy: Bone mineral density as assessed by DEXA scan measured in grams per cubic centimeter with resulting Z score	Change in bone mineral density (BMD) measured by DEXA scan measured in grams per cubic centimeter with resulting Z score.	From inclusion to 12 months of study treatment
Secondary	Interim efficacy: Body composition as assessed by DEXA scan presented as whole body bone mass and soft tissue composition	Change in body composition measured by DEXA scan presented as whole body bone mass and soft tissue composition with ratios of lean mass, body fat, and bone mass.	From inclusion to 12 months of study treatment
Secondary	Interim efficacy: Gut microbiota composition as assessed by 16S rRNA sequencing	Change in gut microbiota by 16S rRNA sequencing or whole genome sequencing of intestinal bacteria.	From inclusion to 4 months of study treatment
Secondary	Interim efficacy: Gut microbiota composition as assessed by 16S rRNA sequencing	Change in gut microbiota by 16S rRNA sequencing or whole genome sequencing of intestinal bacteria.	From inclusion to 12 months of study treatment
Secondary	Interim efficacy: Small intestinal permeability as assessed by urine-lactulose/mannitol measurement and ion chromatography	Change in small intestinal permeability by functional assessment by urine-lactulose/mannitol measurement and ion chromatography or by indirect assessment by qPCR and 16S rRNA sequencing of whole blood.	From inclusion to 4 months of study treatment
Secondary	Interim efficacy: Epigenetic regulation as assessed by levels of 5-mC and 5-hmC	Change in DNA methylation and hydroxymethylation (5-mC and 5-hmC) patterns in hematopoietic cells by global 5-hmC/5-mC assessment and EPIC arrays.	From inclusion to 4 months of study treatment
Secondary	Interim efficacy: Epigenetic regulation as assessed by levels of 5-mC and 5-hmC	Change in DNA methylation and hydroxymethylation (5-mC and 5-hmC) patterns in hematopoietic cells by global 5-hmC/5-mC assessment and EPIC arrays.	From inclusion to 12 months of study treatment
Secondary	Interim efficacy: Gene expression as assessed by RNA sequencing	Change in RNA expression in hematopoietic cells and BM adipocytes.	From inclusion to 4 months of study treatment
Secondary	Interim efficacy: Gene expression as assessed by RNA sequencing	Change in RNA expression in hematopoietic cells and BM adipocytes.	From inclusion to 12 months of study treatment
Secondary	Interim efficacy: Protein profiles as assessed by proteomics	Change in protein profiles in hematopoietic cells and BM adipocytes by proteomics.	From inclusion to 4 months of study treatment
Secondary	Interim efficacy: Protein profiles as assessed by proteomics	Change in protein profiles in hematopoietic cells and BM adipocytes by proteomics.	From inclusion to 12 months of study treatment
Secondary	Interim efficacy: Response and disease progression as according to the IWG response criteria in myelodysplastic neoplasms	Rates of response and disease progression as according to the International Working Group (IWG) response criteria in myelodysplastic neoplasms.	From inclusion to 12 months of study treatment
Secondary	Interim efficacy: Bone marrow niche factor levels as assessed by ELISA	Change in niche factors in bone marrow by ELISA.	From inclusion to 4 months of study treatment
Secondary	Interim efficacy: Bone marrow niche factor levels as assessed by ELISA	Change in niche factors in bone marrow by ELISA.	From inclusion to 12 months of study treatment
Secondary	Interim efficacy: Cytokine levels as assessed by ELISA	Change in cytokine levels in peripheral blood and bone marrow plasma by ELISA.	From inclusion to 4 months of study treatment
Secondary	Interim efficacy: Cytokine levels as assessed by ELISA	Change in cytokine levels in peripheral blood and bone marrow plasma by ELISA.	From inclusion to 12 months of study treatment